XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:    
Total revenue $ 36,161 $ 60,827
Operating costs and expenses:    
Cost of goods sold $ 3,491 $ 4,238
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 74,486 $ 89,018
Selling, general and administrative 34,275 30,564
Total operating costs and expenses 112,252 123,820
Loss from operations (76,091) (62,993)
Interest and other, net    
Interest expense (2,372) (97)
Interest income and other income (expenses), net 1,036 (322)
Total interest and other, net (1,336) (419)
Loss before income taxes (77,427) (63,412)
Provision for income taxes 74 113
Investment income in unconsolidated variable interest entity 796 320
Net loss $ (76,705) $ (63,205)
Net income (loss) per share - basic $ (0.81) $ (0.68)
Net income (loss) per share - diluted $ (0.81) $ (0.68)
Weighted average number of common shares used to calculate net income (loss) per share:    
Basic 94,691 93,043
Diluted 94,691 93,043
License Revenue [Member]    
Revenue:    
Total revenue $ 6,000 $ 22,590
Development and Other Revenue [Member]    
Revenue:    
Total revenue 3,891 11,762
Product Revenue, Net [Member]    
Revenue:    
Total revenue 24,161 18,881
Drug Product Revenue [Member]    
Revenue:    
Total revenue $ 2,109 $ 7,594